Study End Points
nonsquamous NSCLC, tumor
ONCOLOGY, TUMOR
The primary end point was time to treatment, defined as the time from diagnostic program referral to systemic treatment initiation for patients with advanced nonsquamous NSCLC enrolled in the ACCELERATE cohort using ctDNA genotyping prior to pathologic diagnosis compared with a reference cohort of consecutive patients referred to the program in 2018 to 2019, prior to the COVID-19 pandemic. Secondary end points included the frequency of actionable targets identified using plasma ctDNA testing, time to sample collection, and turnaround time of plasma vs tumor tissue profiling for all patients with advanced nonsquamous NSCLC. Actionable alterations were classified according to the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets (ESCAT).